Log in to search using one of your social media accounts:

 

Androgen Deprivation, Radiation After Prostatectomy Tied to Longer Survival Androgen Deprivation, Radiation After Prostatectomy Tied to Longer Survival
Survival after radical prostatectomy for prostate cancer is better among men who undergo androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT), according to a retrospective analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 9, 2017 Category: Surgery Tags: Urology News Source Type: news

Studies aid choice of therapy for localised prostate cancer
Radical prostatectomy associated with worse sexual function and incontinence than external beam radiotherapy Related items fromOnMedica Trial of robotic surgery successful for prostate cancer New risk estimation for prostate cancer improves accuracy Special scan may curb need for first biopsy in 1 in 4 men with prostate cancer New non-surgical treatment for early prostate cancer shows promise (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 22, 2017 Category: UK Health Source Type: news

Augmenix scores reimbursement code for SpaceOar
Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device. The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said. The device is delivered through a small needle as a liquid, which then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient&r...
Source: Mass Device - November 9, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology Augmenix Inc. Source Type: news

ASTRO: Brachytherapy Enough for Mid-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Similar outcomes, fewer side effects vs external beam therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2016 Category: Hematology Source Type: news

Brachytherapy Alone for Intermediate-Risk Prostate Cancer Brachytherapy Alone for Intermediate-Risk Prostate Cancer
Patients with favorable intermediate-risk prostate cancer can be treated with radioactive-seed brachytherapy alone and thus be spared additional late toxicity associated with the usually standard delivery of external-beam radiation first.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Accuray touts 5-year CyberKnife data in prostate cancer trial
Accuray (NSDQ:ARAY) today released 5-year data from a study of its CyberKnife stereotactic body radiotherapy device for treating prostate cancer, touting a 97% rate of freedom from cancer after treatment at 5-years. Results from the study were presented at the American Society for Therapeutic Radiology and Oncology’s annual meeting in Boston. The 21-site, 309-patient trial looked to examine whether dose-escalated SBRT can be administered across multiple institutions without grade 3+ toxicities exceeding 10%. The study followed patients for 5 years and reported toxicity, survival and relapse-free survival outcome...
Source: Mass Device - September 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology Radiosurgery Accuray Inc. Source Type: news

Study Compares Surgery, Radiation, and Active Monitoring to Treat Prostate Cancer
This study will help inform that discussion for men making what is a highly personal, and often difficult choice,” said Brawley.The study involved about 1,600 men in the United Kingdom aged 50 to 69 who were diagnosed with prostate cancer after having an elevated PSA test result. The men were assigned randomly to get surgery to remove their prostate, external-beam radiation, or active monitoring.While the results showed no difference in death from prostate cancer among the groups after 10 years of monitoring, it remains to be seen whether differences will show up after a longer follow-up period. This could be especia...
Source: American Cancer Society :: News and Features - September 16, 2016 Category: Cancer & Oncology Tags: Prostate Cancer Source Type: news

Reflexion adds $6m to bring Series B to $52m
California-based medtech group RefleXion Medical said yesterday it extended its Series B round of financing, bringing in an extra $6 million to bring the total for the round up to $52 million. RefleXion Medical said it is developing a biology-guided radiotherapy system for cancer treatment, which is designed to use positron emission tomography to locate and identify tumors during treatments. “RefleXion’s novel combination of PET imaging and external beam radiation therapy represents a significant innovation in localized cancer treatment. We look forward to identifying compelling clinical applications ...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Oncology RefleXion Medical Source Type: news

IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site. The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available. A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at ...
Source: Mass Device - June 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological Radiosurgery IsoRay Source Type: news

Elekta inks U.S. brachytherapy distro deal with Kobold Medical.
Elekta (STO:EKTA B) said yesterday it inked a distribution deal with Kobold Medical to distribute its brachytherapy applicators within the U.S. Through the deal, Elekta will market and distribute 4 kobold applicators, as well as its prostate template, the company said. “We are pleased to offer our brachytherapy users in the United States these high quality products from Kobold. Adding these solutions to our brachytherapy portfolio will help us better serve the needs of clinical providers,” Elekta North America exec veep Bill Yaeger said in a press release. Included in the distribution deal is Kobold Medica...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Distribution Radiosurgery Elekta AB Kobold Medical Source Type: news

Duke cancer care in Wake County
Treatment Terms Cancer Anal cancer Bile duct cancer Bladder cancer Breast cancer Colon cancer Esophageal cancer Gallbladder cancer Kidney cancer Liver cancer Lung cancer Oral cancer Ovarian cancer Pancreatic cancer Prostate cancer Rectal cancer Skin cancers Skull base tumor Spine cancer Stomach cancer Testicular cancer Throat and voice box cancer Thyroid cancer Tracheal cancer Uterine cancer Vaginal cancer and vulvar cancer Additional SEO Keywords cancer imaging and treatment in Cary...
Source: dukehealth.org: Duke Health News - May 20, 2016 Category: Consumer Health News Authors: dg62 Source Type: news

Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer
Objective: To quantify the journeys and CO emissions if women with breast cancer are treated with risk-adapted single-dose targeted intraoperative radiotherapy (TARGIT) rather than several weeks' course of external beam whole breast radiotherapy (EBRT) treatment. Setting: (1) TARGIT-A randomised clinical trial ( 2 External 0 0 0 ISRCTN34086741 false http://www.controlled-trials.com/ISRCTN34086741 true false%>) which compared TARGIT with traditional EBRT and found similar breast cancer control, particularly when TARGIT was given simultaneously with lumpectomy, (2) 2 additional UK centres offering TARGIT. Participants...
Source: Current Awareness Service for Health (CASH) - May 10, 2016 Category: Consumer Health News Source Type: news

The 'Pinhole' Cancer Treatment You've Probably Never Heard of
Imagine an exquisitely precise cancer therapy procedure done through a small opening in the body that can: Kill tumor cells, shrink tumors, or regrow the healthy part of a cancerous organ. Deliver chemotherapy or radiation directly to the cancer site. Usually be done as an outpatient procedure with fewer side effects than conventional treatments like chemotherapy. Potentially treat many types of cancer, either alone or combined with other therapies. Sounds too good to be true, right? Not necessarily, since this type of therapy, called interventional oncology, is now being performed hundreds of times every day by special...
Source: Science - The Huffington Post - March 30, 2016 Category: Science Source Type: news

Interruption of radiation therapy risks cancer recurrence
Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators have found. The study evaluated 1,227 patients scheduled for courses of external beam radiation therapy for cancers of the head and neck, breast, lung, cervix uterus or rectum from 2007 to 2012. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 9, 2016 Category: Science Source Type: news

Diagnosed With Prostate Cancer, Now What: A New Study Shows That Surgery Is the Best Option
With prostate cancer being one of the leading cancers in men, finding the best way to treat it has become increasingly important. A new study points to why surgery might be the best long term treatment option, especially for men with localized prostate cancer. Researchers from Odette Caner Centre, Sunnybrook Research Institute (University of Toronto, Canada) conducted a meta-analysis of 19 studies comparing the success/survival rates of surgery vs. radiation. All in all, this added up to about 120,000 men who received either surgery or radiation as treatment for their localized prostate cancer. What researchers found was t...
Source: Healthy Living - The Huffington Post - December 17, 2015 Category: Consumer Health News Source Type: news

What is and What To Expect from External Breast...
Read about external beam breast radiation therapy, including what you can expect during a radiation session, potential side effects, and useful coping strategies during recovery. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - October 31, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

FDA clears SonaCare HIFU prostate device, prompts Edap to yank de novo, go for 510k
SonaCare said it won FDA pre market approval for its high intensity focused ultrasound device designed to treat prostate cancer, causing competitor EDAP (NSDQ:EDAP) to yank the de novo application for its Ablatherm HIFU. SonaCare said its Sonablate 450 will be available in the U.S. this October. “The FDA regulatory authorization to market Sonablate in the U.S. is a milestone for non-invasive prostate care and a tremendous gain for men’s health. Men all over the world, in the more than 49 countries where it has already been authorized for use, have had access to this technology for prostate ablation. There ...
Source: Mass Device - October 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology Pre-Market Approval (PMA) Regulatory/Compliance EDAP TMS SA SonaCare Medical Source Type: news

Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 28, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Brachytherapy Boosts Survival in Inoperable Endometrial CancerBrachytherapy Boosts Survival in Inoperable Endometrial Cancer
Women with inoperable early-stage endometrial cancer survive longer if their treatment includes brachytherapy rather than external beam radiotherapy alone. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 27, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Prostate cancer patients who receive permanent radiotherapy implants twice as likely to be free of cancer after five years
Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2015 Category: Science Source Type: news

Permanent radiotherapy implants reduce risk of prostate cancer recurrence after 5 years
(European Society for Radiotherapy and Oncology (ESTRO)) Results from a randomized controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. The research will be presented at the 3rd ESTRO Forum in Barcelona, Spain, (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2015 Category: Cancer & Oncology Source Type: news

Brachytherapy improves survival for inoperable early stage endometrial cancer
Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 26, 2015 Category: Science Source Type: news

Brachytherapy improves survival for inoperable early stage endometrial cancer
(European Society for Radiotherapy and Oncology (ESTRO)) Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2015 Category: Cancer & Oncology Source Type: news

The 6 Injustices of Thyroid Cancer
Imagine if your best friend -- the one who deserves one hell of a co-pay for the psych-worthy advice she doles out on a daily basis (with love and/or or a swift kick in the butt, as needed) suddenly couldn't speak. My lifeline, Jill Gurfinkel, had a paralyzed vocal cord for what seemed like forever. Not from cheering for her then 7-year-old son at his hockey game or yelling at him to eat his vegetables or even from litigating in court (I don't mess around; my chief counsel is a badass lawyer). The only thing that has ever robbed her of her voice was thyroid cancer. In Cindy Finch's recent HuffPost blog, "The 6 Inju...
Source: Healthy Living - The Huffington Post - February 3, 2015 Category: Consumer Health News Source Type: news

Patients treated with radiation therapy who have tumors in left breast have comparable overall survival to those with tumors in right breast
Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 20, 2014 Category: Science Source Type: news

Patients who have left breast tumors have comparable OS to those with right breast tumors
(American Society for Radiation Oncology) Tumor laterality (left-side vs. right-side) does not impact overall survival in breast cancer patients treated with breast-conserving surgery and adjuvant external beam radiation therapy, according to a study published in the Oct. 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news

Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function
(American Society for Radiation Oncology) A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiotherapy versus combination external beam radiotherapy plus brachytherapy, indicates that the utilization of vessel-sparing radiation therapy makes cure possible without compromising long-term sexual function, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2014 Category: Global & Universal Source Type: news

Convenient, less expensive, but possibly riskier new prostate cancer treatment: SBRT
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers - a higher rate of urinary complications.The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation per treatment than IMRT. As a result, patients receiving SBRT can complete an entire course of treatment in one to two weeks, compared to seven to nine weeks for IMRT. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

MammoSite Breast Brachytherapy
MammoSite breast brachytherapy is an alternative radiation treatment to external beam radiation of the breast. MammoSite breast brachytherapy takes 5 days to completely treat early stage breast cancer with radiation after a lumpectomy. Learn more about MammoSite breast brachytherapy here. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 28, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Mixed Results for Brachytherapy in Breast Cancer (CME/CE)
(MedPage Today) -- Older breast cancer patients had an increased rate of subsequent mastectomy if they received brachytherapy instead of external-beam radiation therapy after lumpectomy but fared better than patients who received no radiation, investigators reported. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 7, 2014 Category: Surgery Source Type: news

EBRT reduces risk of subsequent mastectomy in patients with invasive breast cancer
(American Society for Radiation Oncology) Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the Feb. 1, 2014, print edition of the International Journal of Radiation Oncology*Biology*Physics, the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2014 Category: Cancer & Oncology Source Type: news

New breast cancer study: Results of the TARGIT-A clinical trial
A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients."The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment at the time of her operation, with lower toxicity to the breast, the heart and other organs. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Radiation at Surgery Equal to Whole-Breast RT (CME/CE)
(MedPage Today) -- Intraoperative radiation therapy (IORT) for early breast cancer demonstrated noninferiority to whole-breast external beam radiation therapy (EBRT) in two randomized clinical trials. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 11, 2013 Category: Hematology Source Type: news

"One-stop" radiotherapy could offer an alternative to lengthy and inconvenient post-surgery procedures for breast cancer
Two new studies, published in The Lancet and The Lancet Oncology, show that targeted radiotherapy delivered during surgery could offer a viable alternative to current procedures - which require women to attend daily radiotherapy sessions for weeks after surgery - for some women undergoing surgery for early breast cancer. Most women who undergo partial mastectomy (lumpectomy) surgery for breast cancer also complete a course of radiotherapy delivered to the whole of the affected breast (called external beam radiotherapy, EBRT)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Mortality risks not increased by external beam RT in early-stage breast cancer
Early-stage breast cancer patients who receive external beam therapy (XRT) are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study utilized patient information from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 26, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

External beam RT for early-stage breast cancer does not increase mortality risks
(American Society for Radiation Oncology) Early-stage breast cancer patients who receive external beam therapy are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies, according to research presented today at the American Society for Radiation Oncology's 55th Annual Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 24, 2013 Category: Global & Universal Source Type: news

Chemoradiation Therapy for the Treatment of Bone Metastases
The combination of the chemotherapy capecitabine with external beam radiation was found to be both safe and effective in treating pain from bone metastases in patients with advanced breast cancer. (Source: Cancer Network)
Source: Cancer Network - August 2, 2013 Category: Cancer & Oncology Source Type: news

Mortality After Radical Prostatectomy for Prostate CancerMortality After Radical Prostatectomy for Prostate Cancer
For localized prostate cancer, which treatment has better outcomes, radical prostatectomy or external beam radiotherapy? Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Improved Radionuclide Drug Treatment Planning With 3D Patient Models And Quantification Of Therapeutic Dose
External beam radiation treatment has long been manipulated into the unique shape of patients' tumors for personalized cancer care. Technology providing a means of patient-specific radionuclide drug therapies has not been standardized, as it has been limited to software that requires oncologists to manually define the areas of tumors... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Radiology / Nuclear Medicine Source Type: news

Side Effects of External Beam Radiation Therapy...
It is important to understand the potential side effects that may result from external beam radiation therapy (EBRT) for prostate cancer. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news

External Beam Radiation Therapy for Prostate...
Radiation therapy is a commonly-used treatment for prostate cancer. Radiation therapy can be administered from outside the body (external beam radiation therapy) or from inside the body (brachytherapy). (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news

Definition of EBRT (External Beam Radiation...
EBRT - Definition of EBRT (external beam radiation therapy). Learn the meaning of EBRT for prostate cancer. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news

Yes, nanoscience can enhance humans – but ethical guidelines must be agreed
People 'enhanced' into spider-climbing individuals with hugely projected breasts and Einstein-brains… Where will it stop?Engineers are trained to try to figure out how to achieve things that humans cannot and in nanoscience and nanotechnology that challenge is no different.Many of the most exciting advances in the field try to improve human incapacities with things such as memory, hearing, stamina or intellect. In my field of nanomedicine, the notion of human enhancement is, in a lot of cases, a way to deal with disease: enhancing vision, cognitive functions or improving a person's ability to move independently.I ha...
Source: Guardian Unlimited Science - June 3, 2013 Category: Science Authors: Kostas Kostarelos Tags: Blogposts Biology guardian.co.uk Medical research Nanotechnology Human biology Science Source Type: news

New risk classification system proposed for prostate cancer
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - April 29, 2013 Category: Cancer & Oncology Source Type: news

New risk classification system proposed for prostate cancer
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy. (Source: MedWire News - Urology)
Source: MedWire News - Urology - April 29, 2013 Category: Urology & Nephrology Source Type: news

Brachytherapy Boost an Option for Base-of-Tongue CancerBrachytherapy Boost an Option for Base-of-Tongue Cancer
A high-dose-rate interstitial brachytherapy boost after external-beam radiotherapy is associated with 'acceptable' local control and overall survival in base-of-tongue cancer, new research shows. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combination RT offers hope to late-stage esophageal cancer patients
Just over half of patients with advanced-stage esophageal cancer who are unsuitable for standard curative treatment survive for a year after receiving a combination of external beam radiotherapy and high-dose rate brachytherapy, report researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 7, 2013 Category: Cancer & Oncology Source Type: news

Prostatectomy vs Radiotherapy: 15-Year Functional Outcomes Are the Same
Fifteen years after treatment for localized prostate cancer, men who underwent radical prostatectomy reported no differences in urinary, bowel, or sexual function compared with men who underwent external-beam... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 1, 2013 Category: Cancer & Oncology Source Type: news